Sanofi Aventis De Panama S.A. | Reportaje de Proveedor — Panjiva
Más

Supply Chain Intelligence about:

Sanofi Aventis De Panama S.A.

Perfil de la empresa   France

See Sanofi Aventis De Panama S.A.'s products and customers

Thousands of companies like you use Panjiva to research suppliers and competitors.

Fácil acceso a los datos del comercio

Cleaned and organized South American shipments

4 South American shipments available for Sanofi Aventis De Panama S.A.
Fecha fuente de datos Clientes Detalles
2016-07-26 Paraguay Imports
SANOFI AVENTIS PARAGUAY S.A
CLEXANE, CLEXANE 60MG/0.6ML INJ PS2 ERIS XB(ENOXAPARINA)
2019-06-03 Paraguay Imports
SANOFI AVENTIS S.A
SANOFI, LOS DEMAS MEDICAMENTOS PARA USO HUMANO EN,: CLEXANE 80 MG/O 8ML INJ PS2 ERIS XB
2019-06-03 Paraguay Imports
SANOFI AVENTIS S.A
SANOFI, LOS DEMAS MEDICAMENTOS PARA USOHUMANO EN,: CLEXANE 60MG/0.6ML INJ PS2 ERIS XB
El dato de envío muestra cuales productos una empresa usa para el comercio y más. Aprender más

Explore trading relationships hidden in supply chain data


Sample Bill of Lading

4 shipment records available

Bill of Lading Number
XXX 00998578
Shipment Date
2016-07-26
Consignee
Sanofi Aventis Paraguay S.A
Consignee (Original Format)
SANOFI AVENTIS PARAGUAY S.A
Consignee Tax Number
800355741
Shipper
Sanofi Aventis De Panama S.A.
Shipper (Original Format)
SANOFI AVENTIS PARAGUAY SA
Carrier
TAMPA CARGO S.A.
Carrier Country (Original Format)
COLOMBIA
Shipment Origin
France
Shipment Origin (Original Format)
FRANCIA
Port of Unlading
Paraguay (PY)
Country of Sale
Panama
Country of Sale (Original Format)
PANAMA
Transport Method
Air
HS Code
30049099
Goods Shipped
CLEXANE 60MG/0.6ML INJ PS2 ERIS XB(ENOXAPARINA)
Item Quantity
4243
Item Unit
unid.
Gross Weight (kg)
291
Net Weight (kg)
191
Value of Goods, CIF (USD)
$49,856
Value of Goods, FOB (USD)
$47,599
Freight Value (USD)
$2,085
Value of Goods, Item FOB (USD)
$11
Insurance Value (USD)
$173
Manifest Number
16002MANI010727T
Brand
CLEXANE

Recent Panjiva Research about Sanofi Aventis De Panama S.A.

20161202-insulin-us

Novo and Lilly Face Tough Growth in Diabetes, Trade Data Shows

The global prevalence of diabetes is growing, but can be a tough sector for pharmaceutical companies to make money in as recent results from Novo Nordisk and Eli Lilly demonstrate. Panjiva data shows that U.S. imports of insulin and related equipment fell 15% in the third quarter in dollar ter... Read more →